Cellectis SA (ALCLS):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Cellectis SA (ALCLS) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7841
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cellectis SA (Cellectis) is a clinical-stage biopharmaceutical company that research, develop and commercialise rational genome engineering technologies. The company pioneers gene editing company, deploying core proprietary technologies to develop off-the-shelf immunotherapies to target and eradicate cancer cells. It develops treatment based on allogeneic T-cell for the treatment of cancer. Cellectis therapeutic pipeline products include products for hematopoietic tumors such as UCART19, UCART123, UCART33, UCART-BCMA and UCART38; and products for solid tumors including UCART5T4, UCART-EgfrVIII, s-3, s-4, s-5,s-6, and s-7. The company carries out research and development in the field of oncology and gene editing. It operates in New York and Paris. Cellectis is headquartered in Paris, France.

Cellectis SA (ALCLS) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Cellectis SA, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Cellectis SA, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Cellectis SA, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Cellectis SA, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
Cellectis SA, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Cellectis SA, Medical Equipment, Deal Details 10
Partnerships 10
Cellectis bioresearch Enters Into Technology Integration Agreement With Stemgent 10
Equity Offering 11
Cellectis Prices Public Offering of American Depositary Shares for USD228.25 Million 11
Cellectis Completes Private Placement Of Shares For USD24.6 Million 13
Acquisition 14
Pfizer May Acquire Remaining 90.5% Stake in Cellectis 14
Cellectis SA – Key Competitors 15
Cellectis SA – Key Employees 16
Cellectis SA – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Recent Developments 18
Financial Announcements 18
Aug 01, 2018: Cellectis Reports Financial Results for 2nd Quarter and First Six Months 2018 18
May 07, 2018: Cellectis Reports 1st Quarter 2018 Financial Results 22
Mar 12, 2018: Cellectis Reports 4th Quarter and Full Year 2017 Financial Results 25
Nov 13, 2017: Cellectis Reports Financial Results for Third Quarter and First Nine Months of 2017 29
Aug 02, 2017: Cellectis Reports Financial Results for 2nd Quarter and First Six Months 2017 33
May 09, 2017: Cellectis Reports 1st Quarter 2017 Financial Results 35
Mar 06, 2017: Cellectis Reports 4th Quarter and Full Year 2016 Financial Results 37
Corporate Communications 40
Aug 22, 2018: Calyxt appoints Dr. Yves J. Ribeill as Interim CEO 40
Aug 02, 2018: Cellectis Appoints Stefan Scherer M.D., Ph.D., as Senior Vice President Clinical Development and Deputy Chief Medical Officer 41
Mar 13, 2018: Dr. Mathieu Simon to Retire as Cellectis’ Chief Operating Officer; Elsy Boglioli Named as Successor 42
Dec 04, 2017: Cellectis Appoints Elsy Boglioli to Executive Vice President, Strategy and Corporate Development 43
Dec 04, 2017: Cellectis Appoints Immuno-Oncology Leader Stephane Depil to Position of Senior Vice President Research & Development and Chief Medical Officer 44
Oct 04, 2017: Mathieu Simon, M.D. Cellectis’ EVP & Chief Operating Officer, to Serve as Interim Chief Medical Officer 45
Jun 28, 2017: Cellectis Appoints Rainer Boehm, M.D. and Herve Hoppenot to Board of Directors 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
Cellectis SA, Medical Equipment, Key Facts, 2017 2
Cellectis SA, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Cellectis SA, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Cellectis SA, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Cellectis SA, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Cellectis SA, Deals By Market, 2012 to YTD 2018 8
Cellectis SA, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Cellectis bioresearch Enters Into Technology Integration Agreement With Stemgent 10
Cellectis Prices Public Offering of American Depositary Shares for USD228.25 Million 11
Cellectis Completes Private Placement Of Shares For USD24.6 Million 13
Pfizer May Acquire Remaining 90.5% Stake in Cellectis 14
Cellectis SA, Key Competitors 15
Cellectis SA, Key Employees 16
Cellectis SA, Subsidiaries 17

List of Figures
Cellectis SA, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Cellectis SA, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Cellectis SA, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Cellectis SA, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Cellectis SA, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Cellectis SA, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
Cellectis SA, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Cellectis SA, Medical Equipment, Deals by Market, 2012 to YTD 2018 8

★海外企業調査レポート[Cellectis SA (ALCLS):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Gard P & I (Bermuda) Ltd.
    Gard P & I (Bermuda) Ltd. - Strategy, SWOT and Corporate Finance Report Summary Gard P & I (Bermuda) Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • CANbridge Life Sciences Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Canbridge Life Sciences Ltd (Canbridge) is a biopharmaceutical company that offers development and commercialization of specialty healthcare products. The company’s pipeline products include CAN-008, an antibody-like CD95 receptor and Fc-fusion protein used to reduce cancer-cell migration in …
  • Engro Corp Ltd (ENGRO)
    Engro Corp Ltd (ENGRO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Fabric Development Inc:企業の戦略的SWOT分析
    Fabric Development Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • CP All Public Company Ltd (CPALL):企業の財務・戦略的SWOT分析
    CP All Public Company Ltd (CPALL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • PGNiG SA (PGN):企業の財務・戦略的SWOT分析
    PGNiG SA (PGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Tuas Power Ltd:企業の戦略的SWOT分析
    Tuas Power Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Peters Surgical:医療機器:M&Aディール及び事業提携情報
    Summary Peters Surgical (Peters), a subsidiary of Eurazeo SA, is a medical device company that designs, manufactures and distributes surgical products. The company offers products such as catheters, sutures, surgical glue, cardiac ring, single use instrument and accessories for surgical procedures. …
  • PTT Public Co Ltd (PTT):石油・ガス:M&Aディール及び事業提携情報
    Summary PTT Public Co Ltd (PTT) is a state-owned integrated national oil and gas, and petrochemical company. It operates in oil and natural gas, coal, power, and infrastructure businesses. The company carries out oil and natural gas exploration and production; oil refining; procurement, processing, …
  • Lanka IOC PLC (LIOC.N0000):企業の財務・戦略的SWOT分析
    Summary Lanka IOC Plc (LIOC), a subsidiary of Indian Oil Corporation Ltd is an oil and gas company that imports, sells and distributes petroleum products. The company's products include lubricants, fuels, bitumen and bunkering products. It provides automotive lubricants, including passenger car, die …
  • OSI Systems Inc (OSIS):企業の財務・戦略的SWOT分析
    OSI Systems Inc (OSIS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Flint Group SA:企業の戦略的SWOT分析
    Flint Group SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Fortis Inc (FTS):電力:M&Aディール及び事業提携情報
    Summary Fortis Inc (Fortis) is an oil and gas company that provides development of assets and market capitalization programs. The company offers measurement and monitoring of environmental impacts. It also provides capital program and growth plans to meet the energy needs. Fortis support and partici …
  • CAB Incorporated:企業の戦略的SWOT分析
    CAB Incorporated - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Cynvenio Biosystems Inc:医療機器:M&Aディール及び事業提携情報
    Summary Cynvenio Biosystems Inc (Cynvenio) is a cancer diagnostic company that focuses on transforming cancer treatment and management through the molecular analysis of cancer biomarkers in blood. The company offers products such as lab automation systems, isolation products and proprietary informat …
  • Providence Service Corporation:戦略・SWOT・企業財務分析
    Providence Service Corporation - Strategy, SWOT and Corporate Finance Report Summary Providence Service Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Cantargia AB (CANTA):企業の財務・戦略的SWOT分析
    Summary Cantargia AB (Cantargia), a subsidiary of Lund University Bioscience AB is a biotechnology company that develops antibody based cancer treatments. The company’s product candidate CAN04 is used for the treatment of several cancers including non-small cell lung cancer and pancreatic cancer. It …
  • Vallourec Sa
    Vallourec Sa - Strategy, SWOT and Corporate Finance Report Summary Vallourec Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Kingboard Laminates Holdings Limited (1888):企業の財務・戦略的SWOT分析
    Kingboard Laminates Holdings Limited (1888) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key streng …
  • Geron Corp (GERN):企業の財務・戦略的SWOT分析
    Geron Corp (GERN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆